Aastrom Biosciences is a leader in the development of enhanced autologous cellular therapies for use in the treatment of severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology is used to expand naturally occurring populations of stem and progenitor cells derived from the patient's bone marrow. The Aastrom process draws on the human body's own healing mechanisms to produce an expanded mixed-cell therapy that is administered to the same patient. Aastrom is dedicated to developing first-in-class treatments for critical limb ischemia and dilated cardiomyopathy - critical cardiovascular diseases that currently have limited or no treatment options.